Concurrent chemoradiotherapy for patients with postoperative recurrence of surgically resected non-small-cell lung cancer

Tomoyoshi Takenaka, Mitsuhiro Takenoyama, Ryo Toyozawa, Eiko Inamasu, Tsukihisa Yoshida, Gouji Toyokawa, Yoshimasa Shiraishi, Fumihiko Hirai, Masafumi Yamaguchi, Takashi Seto, Yukito Ichinose

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background A few reports have evaluated the outcomes of concurrent chemoradiotherapy (CRT) for patients with postoperative recurrence of non-small cell lung cancer (NSCLC). Patients and Methods From 2000 through 2011, 1237 consecutive patients with NSCLC underwent pulmonary resection at our institution. Of those, 280 patients had experienced postoperative recurrence by the end of 2012. Thirty-five patients received concurrent CRT as initial treatment of the recurrent disease. We retrospectively reviewed these cases, analyzed the outcomes of concurrent CRT after surgical resection, and examined the factors that predict long-term postrecurrence survival. Results The most common sites of recurrence in this cohort were the lymph nodes in 24 patients, followed by the lung in 5 patients and bone in 6 patients. The median radiation dose given as the initial treatment of recurrence was 60 Gy (range, 30-60 Gy). Chemotherapy included a platinum agent in all cases; cisplatin-based chemotherapy was administered in 23 cases, and a carboplatin-based chemotherapy regimen was administered in 12. The median progression-free and postrecurrence survival after CRT was 13 months (range, 4-127 months) and 31 months (range, 5-127 months), respectively. Seven patients were still alive without evidence of disease for > 3 years after the recurrence diagnosis. The ECOG performance status (PS), surgical procedure, and types of platinum agents used were independent prognostic factors for postrecurrence survival. Conclusion Concurrent CRT for recurrent NSCLC is a promising therapy for selected patients. A poor PS and postpneumonectomy state were poor prognostic factors for patients who received concurrent CRT.

Original languageEnglish
Pages (from-to)51-56
Number of pages6
JournalClinical Lung Cancer
Volume16
Issue number1
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Chemoradiotherapy
Non-Small Cell Lung Carcinoma
Recurrence
Platinum
Drug Therapy
Lung
Survival
Carboplatin
Cisplatin
Disease-Free Survival
Therapeutics
Lymph Nodes
Radiation
Bone and Bones

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Takenaka, T., Takenoyama, M., Toyozawa, R., Inamasu, E., Yoshida, T., Toyokawa, G., ... Ichinose, Y. (2015). Concurrent chemoradiotherapy for patients with postoperative recurrence of surgically resected non-small-cell lung cancer. Clinical Lung Cancer, 16(1), 51-56. https://doi.org/10.1016/j.cllc.2014.06.001

Concurrent chemoradiotherapy for patients with postoperative recurrence of surgically resected non-small-cell lung cancer. / Takenaka, Tomoyoshi; Takenoyama, Mitsuhiro; Toyozawa, Ryo; Inamasu, Eiko; Yoshida, Tsukihisa; Toyokawa, Gouji; Shiraishi, Yoshimasa; Hirai, Fumihiko; Yamaguchi, Masafumi; Seto, Takashi; Ichinose, Yukito.

In: Clinical Lung Cancer, Vol. 16, No. 1, 01.01.2015, p. 51-56.

Research output: Contribution to journalArticle

Takenaka, T, Takenoyama, M, Toyozawa, R, Inamasu, E, Yoshida, T, Toyokawa, G, Shiraishi, Y, Hirai, F, Yamaguchi, M, Seto, T & Ichinose, Y 2015, 'Concurrent chemoradiotherapy for patients with postoperative recurrence of surgically resected non-small-cell lung cancer', Clinical Lung Cancer, vol. 16, no. 1, pp. 51-56. https://doi.org/10.1016/j.cllc.2014.06.001
Takenaka, Tomoyoshi ; Takenoyama, Mitsuhiro ; Toyozawa, Ryo ; Inamasu, Eiko ; Yoshida, Tsukihisa ; Toyokawa, Gouji ; Shiraishi, Yoshimasa ; Hirai, Fumihiko ; Yamaguchi, Masafumi ; Seto, Takashi ; Ichinose, Yukito. / Concurrent chemoradiotherapy for patients with postoperative recurrence of surgically resected non-small-cell lung cancer. In: Clinical Lung Cancer. 2015 ; Vol. 16, No. 1. pp. 51-56.
@article{873a36aed2e843b6b2599a1f16c7ee13,
title = "Concurrent chemoradiotherapy for patients with postoperative recurrence of surgically resected non-small-cell lung cancer",
abstract = "Background A few reports have evaluated the outcomes of concurrent chemoradiotherapy (CRT) for patients with postoperative recurrence of non-small cell lung cancer (NSCLC). Patients and Methods From 2000 through 2011, 1237 consecutive patients with NSCLC underwent pulmonary resection at our institution. Of those, 280 patients had experienced postoperative recurrence by the end of 2012. Thirty-five patients received concurrent CRT as initial treatment of the recurrent disease. We retrospectively reviewed these cases, analyzed the outcomes of concurrent CRT after surgical resection, and examined the factors that predict long-term postrecurrence survival. Results The most common sites of recurrence in this cohort were the lymph nodes in 24 patients, followed by the lung in 5 patients and bone in 6 patients. The median radiation dose given as the initial treatment of recurrence was 60 Gy (range, 30-60 Gy). Chemotherapy included a platinum agent in all cases; cisplatin-based chemotherapy was administered in 23 cases, and a carboplatin-based chemotherapy regimen was administered in 12. The median progression-free and postrecurrence survival after CRT was 13 months (range, 4-127 months) and 31 months (range, 5-127 months), respectively. Seven patients were still alive without evidence of disease for > 3 years after the recurrence diagnosis. The ECOG performance status (PS), surgical procedure, and types of platinum agents used were independent prognostic factors for postrecurrence survival. Conclusion Concurrent CRT for recurrent NSCLC is a promising therapy for selected patients. A poor PS and postpneumonectomy state were poor prognostic factors for patients who received concurrent CRT.",
author = "Tomoyoshi Takenaka and Mitsuhiro Takenoyama and Ryo Toyozawa and Eiko Inamasu and Tsukihisa Yoshida and Gouji Toyokawa and Yoshimasa Shiraishi and Fumihiko Hirai and Masafumi Yamaguchi and Takashi Seto and Yukito Ichinose",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.cllc.2014.06.001",
language = "English",
volume = "16",
pages = "51--56",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Concurrent chemoradiotherapy for patients with postoperative recurrence of surgically resected non-small-cell lung cancer

AU - Takenaka, Tomoyoshi

AU - Takenoyama, Mitsuhiro

AU - Toyozawa, Ryo

AU - Inamasu, Eiko

AU - Yoshida, Tsukihisa

AU - Toyokawa, Gouji

AU - Shiraishi, Yoshimasa

AU - Hirai, Fumihiko

AU - Yamaguchi, Masafumi

AU - Seto, Takashi

AU - Ichinose, Yukito

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background A few reports have evaluated the outcomes of concurrent chemoradiotherapy (CRT) for patients with postoperative recurrence of non-small cell lung cancer (NSCLC). Patients and Methods From 2000 through 2011, 1237 consecutive patients with NSCLC underwent pulmonary resection at our institution. Of those, 280 patients had experienced postoperative recurrence by the end of 2012. Thirty-five patients received concurrent CRT as initial treatment of the recurrent disease. We retrospectively reviewed these cases, analyzed the outcomes of concurrent CRT after surgical resection, and examined the factors that predict long-term postrecurrence survival. Results The most common sites of recurrence in this cohort were the lymph nodes in 24 patients, followed by the lung in 5 patients and bone in 6 patients. The median radiation dose given as the initial treatment of recurrence was 60 Gy (range, 30-60 Gy). Chemotherapy included a platinum agent in all cases; cisplatin-based chemotherapy was administered in 23 cases, and a carboplatin-based chemotherapy regimen was administered in 12. The median progression-free and postrecurrence survival after CRT was 13 months (range, 4-127 months) and 31 months (range, 5-127 months), respectively. Seven patients were still alive without evidence of disease for > 3 years after the recurrence diagnosis. The ECOG performance status (PS), surgical procedure, and types of platinum agents used were independent prognostic factors for postrecurrence survival. Conclusion Concurrent CRT for recurrent NSCLC is a promising therapy for selected patients. A poor PS and postpneumonectomy state were poor prognostic factors for patients who received concurrent CRT.

AB - Background A few reports have evaluated the outcomes of concurrent chemoradiotherapy (CRT) for patients with postoperative recurrence of non-small cell lung cancer (NSCLC). Patients and Methods From 2000 through 2011, 1237 consecutive patients with NSCLC underwent pulmonary resection at our institution. Of those, 280 patients had experienced postoperative recurrence by the end of 2012. Thirty-five patients received concurrent CRT as initial treatment of the recurrent disease. We retrospectively reviewed these cases, analyzed the outcomes of concurrent CRT after surgical resection, and examined the factors that predict long-term postrecurrence survival. Results The most common sites of recurrence in this cohort were the lymph nodes in 24 patients, followed by the lung in 5 patients and bone in 6 patients. The median radiation dose given as the initial treatment of recurrence was 60 Gy (range, 30-60 Gy). Chemotherapy included a platinum agent in all cases; cisplatin-based chemotherapy was administered in 23 cases, and a carboplatin-based chemotherapy regimen was administered in 12. The median progression-free and postrecurrence survival after CRT was 13 months (range, 4-127 months) and 31 months (range, 5-127 months), respectively. Seven patients were still alive without evidence of disease for > 3 years after the recurrence diagnosis. The ECOG performance status (PS), surgical procedure, and types of platinum agents used were independent prognostic factors for postrecurrence survival. Conclusion Concurrent CRT for recurrent NSCLC is a promising therapy for selected patients. A poor PS and postpneumonectomy state were poor prognostic factors for patients who received concurrent CRT.

UR - http://www.scopus.com/inward/record.url?scp=84927570677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927570677&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2014.06.001

DO - 10.1016/j.cllc.2014.06.001

M3 - Article

C2 - 25038000

AN - SCOPUS:84927570677

VL - 16

SP - 51

EP - 56

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 1

ER -